Loading...
Market
What will be RAPT Therapeutics stock price at the end of Q1 2025?
4
Resolution / Starting Odds
Below $1.00 • 25%
$1.00 to $1.50 • 25%
$1.51 to $2.00 • 25%
Above $2.00 • 25%
Publicly available stock price data from financial news outlets or stock exchange listings
Story
RAPT Therapeutics Announces $150 Million Private Placement at $0.85/Share, 90.4% Pre-Market Surge, and License Agreement with Shanghai Jemincare
Dec 23, 2024, 01:31 PM
RAPT Therapeutics has announced a $150 million private placement, which includes 176.5 million shares and warrants priced at $0.85 per share. The company also entered an exclusive license agreement with Shanghai Jemincare for its novel long-acting anti-IgE antibody, JYB1904 (RPT904). Under this agreement, RAPT will retain worldwide rights to the drug, excluding mainland China, Hong Kong, Macau, and Taiwan. Jemincare will receive a $35 million upfront payment and could earn up to $672.5 million in milestone payments. Following these announcements, RAPT's stock experienced a significant pre-market increase of 90.4% and was up 74% during trading hours.
View original story
Similar markets
Above $50 • 25%
$30 to $50 • 25%
$10 to $30 • 25%
Below $10 • 25%
Increase by 20% or more • 25%
Increase by less than 20% • 25%
Remain about the same • 25%
Decrease • 25%
Below $10 • 25%
$10 to $15 • 25%
$15 to $20 • 25%
Above $20 • 25%
Below $20 per share • 25%
$20-$24.99 per share • 25%
$25-$29.99 per share • 25%
$30 or above per share • 25%
Below $25 • 25%
$25 - $50 • 25%
$50 - $75 • 25%
Above $75 • 25%
Below $5 • 25%
$5 to $7.49 • 25%
$7.50 to $9.99 • 25%
$10 or above • 25%
Increase by 0-10% • 25%
Increase by 10-20% • 25%
Increase by more than 20% • 25%
Decrease or no change • 25%
Above $10 • 25%
$5 - $10 • 25%
$1 - $5 • 25%
Below $1 • 25%
Below $60 • 25%
$60-$70 • 25%
$70-$80 • 25%
Above $80 • 25%
Increase by more than 10% • 25%
Increase by 0-10% • 25%
No change or decrease • 25%
Decrease by more than 10% • 25%
Above $30 • 25%
$20-$30 • 25%
$10-$20 • 25%
Below $10 • 25%